Related Experiment Video
Updated: Jun 14, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
BRCC36 regulates β-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease
Yalan Li1, Xiaoyue Chen1, Yiqing Xiong1
1Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, #300 Guangzhou Road, 210029, China.
Insights
BRCA1/BRCA2-containing complex subunit 36 (BRCC36) protects against vascular calcification (VC) in chronic kidney disease (CKD) by inhibiting the Wnt/β-catenin pathway. Upregulating BRCC36 may offer a novel therapeutic strategy for VC in CKD patients.
Area of Science:
- Cardiovascular Biology
- Nephrology
- Molecular Biology
Background:
- Vascular calcification (VC) is prevalent in chronic kidney disease (CKD) with no effective pharmaceutical treatments.
- BRCA1/BRCA2-containing complex subunit 36 (BRCC36) is linked to osteoblast differentiation, but its role in VC is unclear.
Purpose of the Study:
- To investigate the role and mechanisms of BRCC36 in the development of VC.
Main Methods:
- Examined BRCC36 expression in human and mouse CKD models and vascular smooth muscle cells (VSMCs).
- Utilized gain- and loss-of-function experiments, Western blotting, qPCR, immunofluorescence, immunohistochemistry, coimmunoprecipitation, and TOPFlash luciferase assays.
- Investigated the regulation of the Wnt/β-catenin pathway by BRCC36.
Main Results:
- BRCC36 expression was reduced in calcified arteries and VSMCs from CKD patients and mice.
- BRCC36 overexpression alleviated VC, while depletion worsened it, inhibiting VSMC osteogenic differentiation.
- BRCC36 inhibited the Wnt/β-catenin pathway by reducing β-catenin ubiquitination; pioglitazone increased BRCC36 and attenuated VC.
Conclusions:
- The BRCC36-β-catenin axis is crucial in VC pathogenesis.
- BRCC36 and β-catenin represent potential therapeutic targets for preventing VC in CKD.
Background:
The prevalence of vascular calcification (VC) in chronic kidney disease (CKD) patients remains substantial, but currently, there are no effective pharmaceutical therapies available. BRCA1/BRCA2-containing complex subunit 36 (BRCC36) has been implicated in osteoblast osteogenic conversion; however, its specific role in VC remains to be fully elucidated. The aim of this study was to investigate the role and underlying mechanisms of BRCC36 in VC.
Methods:
The association between BRCC36 expression and VC was examined in radial arteries from patients with CKD, high-adenine-induced CKD mice, and vascular smooth muscle cells (VSMCs). Western blotting, real-time polymerase chain reaction, immunofluorescence, and immunohistochemistry were used to analyse gene expression. Gain- and loss-of-function experiments were performed to comprehensively investigate the effects of BRCC36 on VC. Coimmunoprecipitation and TOPFlash luciferase assays were utilized to further investigate the regulatory effects of BRCC36 on the Wnt/β-catenin pathway.
Results:
BRCC36 expression was downregulated in human calcified radial arteries, calcified aortas from CKD mice, and calcified VSMCs. VSMC-specific BRCC36 overexpression alleviated calcium deposition in the vasculature, whereas BRCC36 depletion aggravated VC progression. Furthermore, BRCC36 inhibited the osteogenic differentiation of VSMCs in vitro. Rescue experiments revealed that BRCC36 exerts the protective effects on VC partly by regulating the Wnt/β-catenin signalling pathway. Mechanistically, BRCC36 inhibited the Wnt/β-catenin pathway by decreasing the K63-linked ubiquitination of β-catenin. Additionally, pioglitazone attenuated VC partly through upregulating BRCC36 expression.
Conclusions:
Our research results emphasize the critical role of the BRCC36-β-catenin axis in VC, suggesting that BRCC36 or β-catenin may be promising therapeutic targets to prevent the progression of VC in CKD patients.
Related Concept Videos
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

